It is plausible that since TLR-induced signaling inhibitors that target the MyD88 signaling pathway, such as IRAK-M, are produced in response to chronic TLR signaling, CRC cells develop mechanisms to cope with increased IRAK-M expression without undergoing cell death. This evidence concerns the gene IRAK3 and colorectal carcinoma.